CNS Pharmaceuticals, Inc. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported net loss was USD 2.78 million compared to USD 3.61 million a year ago. Basic loss per share from continuing operations was USD 2.1 compared to USD 4.5 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.202 USD | -0.98% | -17.25% | -84.09% |
Apr. 01 | CNS Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Feb. 27 | CNS Pharmaceuticals, Inc. Approves the Appointments to its Board Committees | CI |
1st Jan change | Capi. | |
---|---|---|
-84.09% | 2.17M | |
-1.42% | 41.35B | |
+42.15% | 40.38B | |
+1.97% | 39.05B | |
-14.19% | 26.67B | |
+1.82% | 24.07B | |
-24.55% | 18.36B | |
-4.07% | 11.68B | |
+21.36% | 11.6B | |
+8.20% | 11.15B |
- Stock Market
- Equities
- CNSP Stock
- News CNS Pharmaceuticals, Inc.
- CNS Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022